#cost

Tirzepatide costs $149–$425/mo through telehealth vs $1,086/mo list price for Zepbound. Here's every pricing option with and without insurance.

Foundayo is the first non-peptide GLP-1 pill for weight loss — FDA-approved April 1, 2026. Here's everything you need to know: how it works, clinical trial results, side effects with real percentages, pricing from $149/mo, dosing schedule, and where to get it online.

Ozempic and Wegovy contain the exact same active ingredient — semaglutide — but they're approved for different conditions, come in different doses, and are priced differently. Here's what actually matters when choosing between them.

Medicare will cover Wegovy and Zepbound for weight loss starting July 1, 2026, at a flat $50/month copay. Here is everything you need to know about eligibility, the prior authorization process, how to prepare, and what happens when the BALANCE Model launches in January 2027.

The two most prescribed GLP-1 weight loss drugs go head to head — clinical results, pricing, side effects, insurance, and which one is right for you.

Two of the biggest telehealth platforms now offer branded Wegovy and GLP-1 programs. We compare Ro and Hims on pricing, medications, insurance, clinical support, and what actually changed after the Novo Nordisk lawsuit.

The FDA just approved Eli Lilly's Foundayo (orforglipron) — the only GLP-1 weight loss pill with no food, water, or timing restrictions. Here's what it costs, how it works, and how it compares to Wegovy and Zepbound.

Medicare will begin covering GLP-1 weight loss medications at $50/month starting July 2026. Here's who qualifies, how it works, and what comes next.

From $25/month with a savings card to $1,350 list price — the GLP-1 pricing landscape is confusing. Here's every option with real numbers.

The FDA ended the semaglutide shortage in February 2025, upending the compounded GLP-1 market. Here's what changed, what's legal, and how to choose.